Locus Pharmaceuticals, Inc. Enters into Second Drug Discovery Agreement on Kinases with Ono Pharmaceutical Company, Ltd.

BLUE BELL, Pa.--(BUSINESS WIRE)--Locus Pharmaceuticals, Inc., a clinical stage computationally-based drug design and development company, announced today that it has entered into a second research agreement with Ono Pharmaceutical Co., Ltd. Based on this agreement, Locus will apply its proprietary computational technologies and capabilities in chemistry, biology and crystallography to design and develop IND-directed preclinical drug candidates for Ono. The molecular target is a protein kinase newly selected by Ono. Financial and other terms of the agreement were not disclosed.

Back to news